The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

120 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.EBI
University Of Florence
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI
Philipps-Universit£T Marburg
Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.EBI
University Of Bologna
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.EBI
Technische Universit£T M£Nchen
Synthesis and assay of retro-a4ß1 integrin-targeting motifs.EBI
University Of Bologna
Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).EBI
University Hospital Of Geneva
Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.EBI
University Of Bologna
Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI
Elan Pharmaceuticals
Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.EBI
University Of Ljubljana
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI
Technische Universit£T M£Nchen
One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18.EBI
University Of Troms£
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI
Jerini
Discovery of orally available integrin alpha5beta1 antagonists.EBI
Jerini
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrinavß3 targeted PET tracer based on a cyclic RGD peptide.EBI
University Of Delaware
Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.EBI
Washington University
Synthesis and evaluation of bivalent, peptidomimetic antagonists of theavß3 integrins.EBI
The Methodist Hospital Research Institute
Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics.EBI
Universit£
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.EBI
Chinese Academy Of Medical Sciences And Peking Union Medical College
Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.EBI
University Of Southern California
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.EBI
University Of Naples Federico Ii
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.EBI
Washington University
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.EBI
University Of Southern California
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.EBI
Merck Research Laboratories
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.EBI
Johnson & Johnson Pharmaceutical Research And Development
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.EBI
Merck Research Laboratories
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.EBI
Technische Universit£T M£Nchen
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.EBI
Merck Research Laboratories
Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.EBI
Texas A&M University
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI
Merck Research Laboratories
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.EBI
Merck Research Laboratories
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.EBI
Bayer
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.EBI
Merck Research Laboratories
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.EBI
Merck Research Laboratories
Biphenyls as potent vitronectin receptor antagonists.EBI
Bayer
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.EBI
Merck Research Laboratories
Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.EBI
Basf
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.EBI
Merck Research Laboratories
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.EBI
Merck Research Laboratories
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.EBI
Smithkline Beecham Pharmaceuticals
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.EBI
Universit£
Camptothecins in tumor homing via an RGD sequence mimetic.EBI
Sigma-Tau Industrie Farmaceutiche Riunite
Near-infrared fluorescent divalent RGD ligand for integrinavß3-targeted optical imaging.EBI
Washington University
¹²5I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand ofavß3 integrin as a molecular imaging probe for angiogenesis.EBI
University Of Florence
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI
Astrazeneca
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.EBI
Astrazeneca
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.EBI
Universita Degli Studi Di Bologna
alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.EBI
Universite Catholique De Louvain
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.EBI
Department Of Organic Chemistry Ugo Schiff University Of Firenze Via Della Lastruccia 13
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.EBI
Universit£
Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.EBI
Basf
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.EBI
Johnson & Johnson Pharmaceutical Research And Development
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.EBI
Universit£
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI
3-Dimensional Pharmaceuticals
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI
Genentech
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI
Merck Research Laboratories
RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.EBI
Hoechst Marion Roussel
Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.EBI
University Of Ljubljana
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.EBI
The University Of Tokyo
Small molecule inhibitors of hantavirus infection.EBI
University Of New Mexico School Of Medicine
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.EBI
University Of Florence
Emerging targets in osteoporosis disease modification.EBI
Amgen
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.EBI
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.EBI
Astrazeneca
Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.EBI
Università
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.EBI
Stanford University School Of Medicine
Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).EBI
Pharmacopeia
Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands.EBI
Cancer Research Uk Clinical Centre
Multiple N-methylation by a designed approach enhances receptor selectivity.EBI
Technische UniversitäT MüNchen
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.EBI
Bayer Healthcare
Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.EBI
Università
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI
Jerini
R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.EBI
Pfizer
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.EBI
Pfizer
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.EBI
Pfizer
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.EBI
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.EBI
Pfizer
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.EBI
Pfizer
Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI
Università
Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.EBI
Merck Research Laboratories
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI
Johnson And Johnson Pharmaceutical Research & Development
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.EBI
Johnson & Johnson Pharmaceutical Research & Development
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.EBI
Johnson & Johnson Pharmaceutical Research And Development
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.EBI
Amgen
Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model.EBI
Dainippon Pharmaceutical
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.EBI
Millennium Pharmaceuticals
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.EBI
Pfizer
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI
Nerviano
Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI
Pharmaceutical Research Institute
Molecular model of the alpha(IIb)beta(3) integrin.EBI
Merck Research Laboratories
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.EBI
Merck Research Laboratories
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.EBI
Merck Research Laboratories
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.EBI
Glaxosmithkline
Thiophene-based vitronectin receptor antagonists.EBI
Shire Biochem
Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.EBI
Leiden University
Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.EBI
Basf
Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.EBI
Merck Research Laboratories
Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.EBI
Institut De Recherches Servier
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.EBI
Merck
Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.EBI
Knoll
Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI
Bayer
alpha(v)beta(3) Antagonists based on a central thiophene scaffold.EBI
Aventis Pharma Deutschland
Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.EBI
Cor Therapeutics
Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.EBI
Technische UniversitäT MüNchen
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI
Taisho Pharmaceutical
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI
Celltech Chiroscience
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).EBI
Dupont Pharmaceuticals
Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).EBI
Dupont Pharmaceuticals
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.EBI
Smithkline Beecham Pharmaceuticals
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.EBI
Technische UniversitäT MüNchen
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.EBI
Smithkline Beecham Pharmaceuticals
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.EBI
Smithkline Beecham Pharmaceuticals
Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.EBI
Dupont Pharmaceuticals
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI
Dupont Pharmaceuticals
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI
Smithkline Beecham Pharmaceuticals
Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.EBI
Cor Therapeutics
Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.EBI
Eli Lilly
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI
Smithkline Beecham Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI
Merck Research Laboratories
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI
Telios Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI
Merck Research Laboratories